NASDAQ : NEO
NeoGenomics, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 17.93 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.30B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.25B |
| Enterprise Value | 2.56B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 129.39M |
| Shares Outstanding | 129.39M |
| Shares Change (YoY) | +1.00% |
| Shares Change (QoQ) | -1.72% |
| Owned by Insiders (%) | 2.14% |
| Owned by Institutions (%) | 106.96% |
| Float | 117.92M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 61.07 |
| PS Ratio | 2.85 |
| Forward PS | 2.60 |
| PB Ratio | 2.80 |
| P/TBV Ratio | 172.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 525.42 |
| PEG Ratio | 1.06 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.25 |
| EV / EBITDA | 112.40 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.53 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 14.64 |
| Debt / FCF | n/a |
| Interest Coverage | -13.29 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -3.94% |
| Return on Assets (ROA) | -1.96% |
| Return on Invested Capital (ROIC) | -3.92% |
| Return on Capital Employed (ROCE) | -3.42% |
| Weighted Average Cost of Capital (WACC) | 11.82% |
| Revenue Per Employee | $315,101 |
| Profits Per Employee | -$12,918 |
| Employee Count | 2,500 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 16.13 |
Taxes
| Measure | Value |
|---|
| Income Tax | -3.88M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.78 |
| 52-Week Price Change | +69.07% |
| 50-Day Moving Average | 17.68 |
| 200-Day Moving Average | 12.78 |
| Relative Strength Index (RSI) | 50.97 |
| Average Volume (20 Days) | 2,179,631 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14.22M |
| Short Previous Month | 14.15M |
| Short % of Shares Out | 10.99% |
| Short % of Float | 12.05% |
| Short Ratio (days to cover) | 5.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 787.75M |
| Gross Profit | 352.67M |
| Operating Income | -43.13M |
| Pretax Income | -36.18M |
| Net Income | -32.30M |
| EBITDA | 22.76M |
| EBIT | -43.13M |
| Loss Per Share | -$0.25 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 139.28M |
| Total Debt | 449.14M |
| Net Cash | -309.86M |
| Net Cash Per Share | -$2.39 |
| Equity (Book Value) | 800.64M |
| Book Value Per Share | 6.20 |
| Working Capital | 293.91M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 4.28M |
| Capital Expenditures | -32.86M |
| Depreciation & Amortization | 65.89M |
| Net Borrowing | 42.09M |
| Free Cash Flow | -28.58M |
| FCF Per Share | -$0.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | 44.77% |
| Operating Margin | -5.47% |
| Pretax Margin | -4.59% |
| Profit Margin | -4.10% |
| EBITDA Margin | 2.89% |
| EBIT Margin | -5.47% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.00% |
| Shareholder Yield | -1.00% |
| Earnings Yield | -1.44% |
| FCF Yield | -1.27% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.78 |
| Price Target Difference | 36.82% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 10.05% |
| EPS Growth Forecast (3Y) | 50.79% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.86 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |